Conditions: Squamous Cell Carcinoma Head and Neck Cancer Recurrent Disease
Keywords: SCCHN Head and Neck Cancer Squamous Cell Carcinoma Recurrent
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 5
Healthy volunteers: no

Brief summary:
Whether low-dose radiation in addition to Taxotere and Erbitux improves the response rate of patients with recurrent unresectable head and neck squamous cell carcinoma.

Detailed description:
The investigator's approach is based on the following reasons:

* Low dose hyper-radiation sensitivity response will be significantly enhanced in Taxotere- induced G2/M cell cycle arrest.
* LDFRT will render enhanced bax activation mediated mode of cell death.
* Erbitux will arrest the cells in G1/G0 phase leading to p21-mediated mode of cell death.
* The toxicity profile is expected to be minimal.

Based on the above mentioned reasons, we propose this novel schema of treatment in recurrent SCCHN.

Arms:
arm 1: Erbitux, Taxotere and Low Dose Fractionated Radiation Therapy (LDFRT)

Interventions: intervention 1: Erbitux intervention 2: Taxotere intervention 3: Low Dose Fractionated Radiation Therapy
Intervention descriptions: intervention 1: Erbitux: 400 mg/m2 as a loading dose one week prior to radiation and taxotere, and then at 250 mg/m2 given weekly on Day 1 of treatment week following Taxotere. intervention 2: Taxotere : 20 mg/m2 IV once a week on Day 1 during treatment weeks 2 to 7. intervention 3: Low-dose fractionated Radiation (LDFRT): 0.5 Gy per fraction twice-a-day (BID) at least 6 to 8 hours apart on Days 2 and 3 of treatment weeks 2 to 7 for a total dose of 12 Gy.

Protocol document: